Evaluating Diversity in Randomized Clinical Trials of Dolutegravir-Based Antiretroviral Therapy Regimens: Pooled 48-Week Analyses by Race, Sex, and Regional Subgroups.
demographics
dolutegravir
integrase strand transfer inhibitor
pooled analysis
regional analysis
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
31
03
2022
accepted:
22
06
2022
entrez:
1
9
2022
pubmed:
2
9
2022
medline:
2
9
2022
Statut:
epublish
Résumé
In HIV clinical trials, proportions of Black and female participants achieving virologic suppression (VS) are often lower compared with White and male participants. As the antiretroviral therapy (ART) landscape continues to evolve, addressing existing challenges in clinical trial diversity will be critical to effectively translate results into clinical practice. Here, we pooled data to evaluate the efficacy and safety of dolutegravir (DTG)-containing regimens by race, sex, and regional subgroups. Three pooled analyses were conducted using 48-week results from phase 3/3b trials: DTG 3-drug vs non-DTG-containing 3- or 4-drug regimens in ART-naive participants (ARIA, FLAMINGO, SINGLE, SPRING-2), DTG-containing 2-drug vs 3-drug regimens in ART-naive participants (GEMINI-1, GEMINI-2), and DTG 3-drug vs non-DTG-containing 3- or 4-drug regimens in ART-experienced participants (SAILING, DAWNING). Proportions of participants with VS, safety, and change from baseline in CD4+ cell count were analyzed. Proportions of participants achieving VS were high among those receiving DTG vs comparator regimens. Proportions of participants achieving VS were generally lower in Black (vs non-Black), female (vs male), and US (vs non-US) subgroups. No new safety signals emerged from any subgroup in pooled analyses. These analyses confirm that, across subgroups, DTG has robust efficacy and a good safety profile at week 48 relative to comparator regimens. Achieving VS may vary by participant characteristics, highlighting the urgent need for enrollment to reflect the demographics of global HIV populations more accurately. Future studies should strive to support participants throughout the trial to ensure optimal representation, inclusion, and retention.
Sections du résumé
Background
UNASSIGNED
In HIV clinical trials, proportions of Black and female participants achieving virologic suppression (VS) are often lower compared with White and male participants. As the antiretroviral therapy (ART) landscape continues to evolve, addressing existing challenges in clinical trial diversity will be critical to effectively translate results into clinical practice. Here, we pooled data to evaluate the efficacy and safety of dolutegravir (DTG)-containing regimens by race, sex, and regional subgroups.
Methods
UNASSIGNED
Three pooled analyses were conducted using 48-week results from phase 3/3b trials: DTG 3-drug vs non-DTG-containing 3- or 4-drug regimens in ART-naive participants (ARIA, FLAMINGO, SINGLE, SPRING-2), DTG-containing 2-drug vs 3-drug regimens in ART-naive participants (GEMINI-1, GEMINI-2), and DTG 3-drug vs non-DTG-containing 3- or 4-drug regimens in ART-experienced participants (SAILING, DAWNING). Proportions of participants with VS, safety, and change from baseline in CD4+ cell count were analyzed.
Results
UNASSIGNED
Proportions of participants achieving VS were high among those receiving DTG vs comparator regimens. Proportions of participants achieving VS were generally lower in Black (vs non-Black), female (vs male), and US (vs non-US) subgroups. No new safety signals emerged from any subgroup in pooled analyses.
Conclusions
UNASSIGNED
These analyses confirm that, across subgroups, DTG has robust efficacy and a good safety profile at week 48 relative to comparator regimens. Achieving VS may vary by participant characteristics, highlighting the urgent need for enrollment to reflect the demographics of global HIV populations more accurately. Future studies should strive to support participants throughout the trial to ensure optimal representation, inclusion, and retention.
Identifiants
pubmed: 36046700
doi: 10.1093/ofid/ofac304
pii: ofac304
pmc: PMC9423381
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofac304Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Lancet HIV. 2017 Dec;4(12):e536-e546
pubmed: 28729158
HIV Clin Trials. 2014 Jan-Feb;15(1):14-26
pubmed: 24518211
Germs. 2017 Sep 1;7(3):113-114
pubmed: 28932710
J Natl Med Assoc. 2010 Jun;102(6):493-9
pubmed: 20575215
AIDS Patient Care STDS. 2010 Jun;24(6):373-80
pubmed: 20515415
Lancet. 2019 Jan 12;393(10167):143-155
pubmed: 30420123
JAMA. 2020 Oct 27;324(16):1651-1669
pubmed: 33052386
AIDS Patient Care STDS. 2009 Oct;23(10):859-65
pubmed: 19799493
PLoS One. 2018 Jan 2;13(1):e0189973
pubmed: 29293632
MMWR Morb Mortal Wkly Rep. 2018 Feb 02;67(4):113-118
pubmed: 29389918
Lancet. 2013 Aug 24;382(9893):700-8
pubmed: 23830355
Euro Surveill. 2019 Nov;24(48):
pubmed: 31796153
Lancet Infect Dis. 2019 Mar;19(3):253-264
pubmed: 30732940
Clin Infect Dis. 2013 Dec;57(11):1607-17
pubmed: 24046302
N Engl J Med. 2013 Nov 7;369(19):1807-18
pubmed: 24195548
J Gen Intern Med. 2007 Jan;22(1):17-42
pubmed: 17351837
AIDS Patient Care STDS. 2020 Sep;34(9):399-416
pubmed: 32931317
Lancet. 2014 Jun 28;383(9936):2222-31
pubmed: 24698485
PLoS One. 2013 Dec 31;8(12):e83649
pubmed: 24391803
J Natl Med Assoc. 2007 Mar;99(3):242-50
pubmed: 17393948
J Acquir Immune Defic Syndr. 2009 Dec;52(5):574-80
pubmed: 19755913
Lancet. 2013 Mar 2;381(9868):735-43
pubmed: 23306000
AIDS. 2022 Jan 1;36(1):39-48
pubmed: 34534138